Life at Zymeworks


Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy

Zymeworks Team Carries the Journey of Hope Torch to Hope, Canada

Zymeworks Supports Dave’s 15,000 Mile Journey of Hope

Zymeworks to Present at Jefferies Virtual Healthcare Conference

Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

FDA Clears Zanidatamab Phase 3 Pivotal Trial in First Line HER2-positive Gastroesophageal Adenocarcinoma

Zymeworks Reports 2021 First Quarter Financial Results

Zymeworks to Present at Bloom Burton Healthcare Conference

Zymeworks Introduces Fourth Therapeutic Platform, ProTECT™

Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual Meeting

Congratulations to Zymeworks Scientist Anna von Rossum, Healthcare Business Women’s Association 2021 Rising Star!

Zymeworks is Proud of Two National Top Employer Recognitions Received in Canada, and Even Prouder of Our People Who Make Zymeworks Such a Great Place to Work!